Source: Contract Pharma

Ability Pharma: AbilityPharma Completes 7M Investment Round

Funding will allow the company to fully finance its phase 2b clinical study of antitumor compound ABTL0812 in patients with pancreatic cancer.

Read full article »
Ability Pharma's Competitors | Ability Pharma's News | Ability Pharma's Financials
Stay up-to-date with the latest news on Ability Pharma
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Carles Domenech's photo - Co-Founder & CEO of Ability Pharma

Co-Founder & CEO

Carles Domenech

CEO Approval Rating

86/100

Read more
Stay up-to-date with the latest news on Ability Pharma